BioPharmSignal logoBioPharmSignal

Biotech News

T2 Biosystems, Inc. and Prxcision, Inc. Announce Co-Marketing Collaboration for Rapid Direct-From-Blood Diagnostics and AI-Powered Decision Support Platform

T2 Biosystems (TTOO)T2 BiosystemsPartnership

Pioneering a new frontier in antibiotic stewardship to combat the growing threat of antimicrobial resistance LEXINGTON, Mass. and SCHENECTADY, N.Y. , Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic

Related news

BJDXBluejay Diagnostics2026-06-02 10:30 EST

Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

BIAFbioAffinity Technologies, Inc.2026-07-22 12:08 EST

bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD

BIAFbioAffinity Technologies, Inc.2026-04-28 13:16 EST

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment

DGXQuest Diagnostics2026-03-12 20:07 EST

Quest Diagnostics Elects Timothy Wentworth, Former CEO of Walgreens Boots Alliance, Evernorth Health Services and Express Scripts, to Board of Directors

INBSIntelligent Bio Solutions2026-02-25 13:45 EST

Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry

INBSIntelligent Bio Solutions2025-12-31 13:45 EST

Intelligent Bio Solutions Announces New Manufacturing Partnership to Strengthen Global Production Capability and Increase Margins

DGXQuest Diagnostics2026-08-24 11:24 EST

Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology

LUCDLucid Diagnostics2026-08-05 12:46 EST

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

BJDXBluejay Diagnostics2026-03-06 11:30 EST

Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook

LUCDLucid Diagnostics2026-07-30 12:30 EST

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

View all latest news

T2 Biosystems

T2 Biosystems is a medical diagnostics company focused on rapid pathogen detection and bloodstream infection testing. Its business is centered on delivering fast diagnostic information to clinical settings.

Recent company news

TTOOT2 Biosystems2025-01-07 14:00 EST

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

TTOOT2 Biosystems2024-12-18 14:00 EST

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

TTOOT2 Biosystems2024-12-17 14:00 EST

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

TTOOT2 Biosystems2024-12-16 14:00 EST

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

TTOOT2 Biosystems2024-12-09 14:00 EST

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Stock data

Close
0.00 USD
Market cap
—
Exchange
NASDAQ
Sector
MedTech
Location
United States